PRRT2 and cancer: When the Cancer Therapeutics Response Portal dataset was used, a correlation between SPTBN2 levels and drug sensitivity showed that Afatinib (a tyrosine kinase inhibitor) and Belinostat (a HDAC inhibitor) negatively correlated with SPTBN2 expression, yet positively correlated with Staurosporine (a PKC inhibitor) (Supplemental Fig. 3b).